PMID- 32532615
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 2095-4964 (Print)
VI  - 18
IP  - 4
DP  - 2020 Jul
TI  - Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and 
      sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort 
      study.
PG  - 319-325
LID - S2095-4964(20)30055-8 [pii]
LID - 10.1016/j.joim.2020.05.003 [doi]
AB  - OBJECTIVE: Sorafenib has been extensively used for the treatment of advanced 
      hepatocellular carcinoma (HCC), and Chinese herbal medicine has also been used to 
      manage advanced HCC. The present work evaluates the effectiveness and safety of 
      Jiedu (JD) Granule, a compound of traditional Chinese herbal medicine, 
      side-by-side with sorafenib for the treatment of advance HCC. METHODS: Patients 
      with advanced HCC receiving treatment with JD Granule or sorafenib were enrolled 
      from December 2014 to March 2018. The primary endpoint was overall survival (OS). 
      The secondary endpoints were progression-free survival (PFS) and safety. 
      Propensity score matching (PSM) analysis was used to control for possible 
      selection bias from the study group allocation process. RESULTS: Of the 325 
      patients included, 161 received JD Granule and 164 received sorafenib. No 
      significant differences were found in OS or PFS among patients receiving JD 
      Granule compared to sorafenib (P > 0.05). Median OS of the two study groups was 
      6.83 months (95% confidence interval [CI]: 5.83-9.47) in the group receiving JD 
      Granule and 8 months (95% CI: 6.67-9.80) in the group receiving sorafenib, with 
      half-, 1- and 2-year survival rates of 53.6%, 31.2% and 13.2% vs 60.1%, 35.5% and 
      14.2%, respectively. Even after PSM, the median survival time did not differ 
      between the JD Granule group (9.03 months; 95% CI: 6.37-14.2) and the sorafenib 
      group (7.93 months; 95% CI: 6.5-9.97), with comparable half-, 1- and 2-year 
      survival rates. The most common adverse events (AEs) were diarrhea (13.7%) and 
      fatigue (5.6%) in the JD Granule group, and hand-foot skin reaction (46.3%) and 
      diarrhea (36.6%) in the sorafenib group. The JD Granule was more cost-effective 
      than sorafenib treatment for advanced HCC. CONCLUSION: Compared to sorafenib, JD 
      Granule was more cost-effective and caused fewer AEs for the treatment of Chinese 
      patients with advanced HCC.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Zhao, He-Tong
AU  - Zhao HT
AD  - School of Traditional Chinese Medicine, Naval Medical University, Shanghai 
      200433, China.
FAU - Meng, Yong-Bin
AU  - Meng YB
AD  - School of Traditional Chinese Medicine, Naval Medical University, Shanghai 
      200433, China.
FAU - Zhai, Xiao-Feng
AU  - Zhai XF
AD  - School of Traditional Chinese Medicine, Naval Medical University, Shanghai 
      200433, China.
FAU - Cheng, Bin-Bin
AU  - Cheng BB
AD  - School of Traditional Chinese Medicine, Naval Medical University, Shanghai 
      200433, China.
FAU - Yu, Sha-Sha
AU  - Yu SS
AD  - School of Traditional Chinese Medicine, Naval Medical University, Shanghai 
      200433, China.
FAU - Yao, Man
AU  - Yao M
AD  - School of Traditional Chinese Medicine, Naval Medical University, Shanghai 
      200433, China.
FAU - Yin, Hui-Xia
AU  - Yin HX
AD  - School of Traditional Chinese Medicine, Naval Medical University, Shanghai 
      200433, China.
FAU - Wan, Xu-Ying
AU  - Wan XY
AD  - Department of Integrated Traditional Chinese and Western Medicine, Eastern 
      Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200433, China.
FAU - Yang, Yun-Ke
AU  - Yang YK
AD  - Department of Integrative Medicine, Zhongshan Hospital, Fudan University, 
      Shanghai 200032, China.
FAU - Liu, Hui
AU  - Liu H
AD  - The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, 
      Naval Medical University, Shanghai 200433, China.
FAU - Shen, Feng
AU  - Shen F
AD  - The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, 
      Naval Medical University, Shanghai 200433, China. Electronic address: 
      shenfengehbh@sina.com.
FAU - Ling, Chang-Quan
AU  - Ling CQ
AD  - School of Traditional Chinese Medicine, Naval Medical University, Shanghai 
      200433, China. Electronic address: changquanling@smmu.edu.cn.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200528
PL  - Netherlands
TA  - J Integr Med
JT  - Journal of integrative medicine
JID - 101603118
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - *Drugs, Chinese Herbal/therapeutic use
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
MH  - Prospective Studies
MH  - *Sorafenib/therapeutic use
OTO - NOTNLM
OT  - Carcinoma, hepatocellular
OT  - Chinese herbal medicine
OT  - Jiedu Granule
OT  - Sorafenib
EDAT- 2020/06/14 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/06/14 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - S2095-4964(20)30055-8 [pii]
AID - 10.1016/j.joim.2020.05.003 [doi]
PST - ppublish
SO  - J Integr Med. 2020 Jul;18(4):319-325. doi: 10.1016/j.joim.2020.05.003. Epub 2020 
      May 28.